Another R&D project has been canceled. Will sh pharma's R&D funding of 115 million yuan be wasted? | Quick read announcement

Tonight, sh pharma announced that it has decided to terminate clinical trials and subsequent development of four research and development projects involving indications such as B-cell non-Hodgkin's lymphoma and multiple sclerosis. The accumulated research and development investment in the early stage has reached 115 million yuan. Industry experts believe that factors such as effectiveness not meeting expectations, better effects of similar competing products, and increased uncertain factors in research and development may cause the company to terminate its in-research projects.

cls.cnJun 7 20:33

A rumor caused medicine to collapse, and the once flocked star funds fled one after another. Who else is still holding on to it?

① Compared with the high on May 17, 2021, Changchun Hi-Tech's stock price has already dropped 78.75%. The stock price of up to 520 yuan three years ago, and a market value of over 210 billion yuan, seems so far away now; ② In the past three years, apart from individual index funds that still ranked among the top ten tradable shareholders, many star products that held this stock heavily in the past have already embraced the new “value depression.”

cls.cnMay 30 18:54

The quarterly adjustment of the MSCI Index excludes 15 Hong Kong stocks. The effective date is scheduled for early June

① Which individual stocks will MSCI China adjust quarterly? ② How much impact does the MSCI Index have on the market?

cls.cnMay 16 08:34

Good payback? Zhifei Biotech calls on domestic nine-valent HPV vaccine manufacturers to participate in the promotion | Direct access to the performance conference

① Whether the imported MSD nine-valent HPV vaccine will be impacted by domestic brands in the future is the primary concern of investors at today's Zhifei Biotech performance conference. ② Chairman Jiang Rensheng said that the HPV vaccine market space is huge, and more manufacturers participating in the promotion will be helpful to the company. ③ Financial Director Li Zhenjing believes that the company's high accounts receivable and inventory growth in the first quarter were due to the expansion of sales and business scale.

cls.cnMay 14 21:36

Are exclusive varieties of traditional Chinese medicine being reduced by Bu Chang Xinxin Online to be included in medical insurance fee control?

① Exclusive medical insurance price adjustments such as Brain Mind, Compound Salvia Drops, Dengzhan Xixin Injection, etc. Are exclusive varieties of traditional Chinese medicine also beginning to be covered by medical insurance fee control? ② Some experts said that as the product patent protection period is approaching, pharmaceutical companies may take the initiative to lower product prices to guarantee an advantageous competitive position in the market to prevent generic drugs from competing for the market after the patent expires.

cls.cnMay 7 20:33

Gao Yi's path to transfer positions came to light. Qiu Guolu, Feng Liu, and Deng Xiaofeng each reduced their holdings, and chemical and pharmaceutical stocks frequently increased their positions

① Feng Liu has continuously reduced his holdings of Hikvision, Zhongju Hi-Tech, and Baofeng Energy, and increased his holdings of pharmaceutical and chemical stocks in the first quarter; ② Deng Xiaofeng reduced his holdings of Zijin Mining, Yunlu, and China Aluminum by 3 mining stocks and has withdrawn from the top ten tradable shareholders of Wanhua Chemical; ③ Qiu Guolu also continuously reduced his holdings in the mining industry Tiandi Technology.

cls.cnApr 28 18:21